The publisher explores Ionis Pharmaceuticals’ prescription pharmaceutical performance and outlook over 2019-29.
Snapshot
Model updates (4 November 2020)
Model updates (5 August 2020)
Model updates (6 May 2020)
Model updates (26 February 2020)
Snapshot
- Overview - Ionis’s prescription pharmaceutical business will see strong growth over the forecast period.
- Key themes - [1] Spinraza royalties will comprise the majority of Ionis’s revenues for the foreseeable future [2] Pharmaceutical business growth driven by launches of Tegsedi and Waylivra.
Model updates (4 November 2020)
- Tegsedi forecast adjusted lower
Model updates (5 August 2020)
- Tegsedi forecast adjusted lower due to sales trends
- Waylivra forecast adjusted lower due to sales trends
- Other revenue adjusted lower due to lower upfront licensing fees.
Model updates (6 May 2020)
- No changes to forecast.
Model updates (26 February 2020)
- Waylivra forecast adjusted lower due to slower-than-anticipated launch.
Table of Contents
Company Background
Recent Earnings Review
Company Forecast
Company Profile
Clinical Trial Overview
